Table 2.
Table 2 shows disease-free survival at 3 years ± 2 standard error according to KIR match or mismatch determined using three different models to define mismatch (receptor ligand match; ligand ligand mismatch and missing ligand). Models of favorable and unfavorable haplotypes are also presented.
| Model | Marrow Transplants | UCB Transplants | All Patients | ||||
|---|---|---|---|---|---|---|---|
| KIR Match | KIR Mismatch | KIR Match | KIR Mismatch | KIR Match | KIR Mismatch | Match vs mismatch p-value | |
| Receptor ligand match | 40 ± 22% (N=20) |
43 ± 16% (N=37) |
40 ± 44% (N=5) |
89 ± 21% (N=9) |
40 ± 20% (N=25) |
50 ± 15% (N=48) |
0.687 |
| Ligand/ligand mismatch | 41 ± 13% (N=61) |
0% (N=4) |
42 ± 27% (N=14) |
100% (N=5) |
40 ± 11% (N=77) |
56 ± 33% (N=9) |
0.360 |
| Missing ligand | 43 ± 22% (N=21) |
31 ± 15% (N=45) |
29 ± 34% (N=7) |
77 ± 23% (N=13) |
39 ± 18% (N=28) |
45 ± 13% (N=60) |
0.981 |
| Haplotype | A/B+B/B | A/A | A/B+B/B | A/A | A/B+B/B | A/A | A/A+B/B vs AA p-value |
| KIR haplotype (centromeric)* | 51 ± 19% (N=27) |
33 ± 17% (N=30) |
38 ± 34% (N=8) |
88 ± 23% (N=8) |
48 ± 17% (N=35) |
43 ± 16% (N=40) |
0.529 |
| KIR haplotype (telomeric)* | 41 ± 23% (N=19) |
42 ± 16% (N=38) |
56 ± 33% (N=9) |
71 ± 34% (N=7) |
46 ± 19% (N=28) |
45 ± 15% (N=47) |
0.600 |
*
Centromeric A haplotypes are defined as those that contain KIR2DL3 and telomeric A haplotypes as those with KIR3DL1. Centromeric B haplotypes are defined as those that contain KIR2DL2 and telomeric B haplotypes as those with KIR3DS1. Two cases received PBSC and are not included in the bone marrow and cord blood analyses (n=82) but do appear in the “all patients” analysis (n= 84).